by Stacey Hawkins | Apr 14, 2020 | Neuroscience
Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and... 
by Stacey Hawkins | Apr 12, 2020 | Neuroscience
Hope on the horizon for HUNTINGTON’S No question about it, Huntington’s disease (HD) is cruel. In the beginning, sufferers of this fatal neurodegenerative disorder experience involuntary movement and mood disturbance, most often in the form of depression. As the... 
by Stacey Hawkins | Jan 28, 2020 | Neuroscience
Getting old is for the birds. Time has its way with nearly every part of us: skin, hair, muscles. Few changes are more alarming, however, than those to our eyes. There’s more to old eyes than bifocals and cataracts though. One of the most common eye diseases is... 
by Stacey Hawkins | Sep 23, 2019 | Neuroscience
Alzheimer’s Disease: The Way Forward Last week, we reviewed the pathology and genetics of Alzheimer’s disease (AD), and discussed the two most common AD drug development targets, amyloid-beta plaques and tau. This week, we’ll take a look at a variety of novel AD drug... 
by Stacey Hawkins | Sep 17, 2019 | Neuroscience
Alzheimer’s disease: A tough nut to crack September 21 is World Alzheimer’s Day, a day focused on raising awareness of Alzheimer’s disease (AD). This week and next, we’ll review what is known about AD, and summarize novel treatments in development. Alzheimer’s... 
by Stacey Hawkins | Jun 7, 2018 | Neuroscience
FIRST IN CLASS MIGRAINE APPROVAL Last month the FDA approved Amgen’s (Thousand Oaks, CA) new migraine drug Aimovig, the first drug shown to prevent the onset of migraines. The drug significantly reduces the number of migraine days in difficult-to-treat (those...
